IRIS UniCatt

Gentile, Marino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.048
AS - Asia 833
EU - Europa 562
SA - Sud America 168
AF - Africa 22
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 2.640
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.013
SG - Singapore 437
SE - Svezia 171
BR - Brasile 138
CN - Cina 115
IT - Italia 90
VN - Vietnam 78
FR - Francia 77
DE - Germania 69
IN - India 57
IE - Irlanda 42
GB - Regno Unito 36
ID - Indonesia 27
JP - Giappone 24
CA - Canada 16
BD - Bangladesh 14
AR - Argentina 13
HK - Hong Kong 12
MX - Messico 12
ZA - Sudafrica 11
AT - Austria 10
RU - Federazione Russa 10
TR - Turchia 10
FI - Finlandia 9
PK - Pakistan 8
IQ - Iraq 7
KR - Corea 7
LT - Lituania 7
PL - Polonia 7
UA - Ucraina 7
UZ - Uzbekistan 6
JO - Giordania 5
VE - Venezuela 5
AU - Australia 4
ES - Italia 4
MA - Marocco 4
NL - Olanda 4
BE - Belgio 3
CZ - Repubblica Ceca 3
EC - Ecuador 3
GR - Grecia 3
KZ - Kazakistan 3
LV - Lettonia 3
SA - Arabia Saudita 3
BO - Bolivia 2
CH - Svizzera 2
CL - Cile 2
CO - Colombia 2
DZ - Algeria 2
ET - Etiopia 2
GE - Georgia 2
MY - Malesia 2
NP - Nepal 2
PH - Filippine 2
RO - Romania 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
EG - Egitto 1
EU - Europa 1
HN - Honduras 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KE - Kenya 1
LK - Sri Lanka 1
MD - Moldavia 1
MM - Myanmar 1
NG - Nigeria 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 2.640
Salva come PNG Salva come JPEG
Città #
Singapore 280
Chandler 183
San Jose 106
Ashburn 88
New York 59
Tukwila 46
Dublin 34
Beijing 31
Los Angeles 31
Frankfurt am Main 30
Hyderabad 29
Ho Chi Minh City 26
Lauterbourg 26
Jakarta 24
Tokyo 24
Dallas 22
Princeton 21
Milan 18
Hanoi 17
San Mateo 16
São Paulo 15
Wilmington 15
Marseille 13
Düsseldorf 12
Florence 12
Hefei 12
Dearborn 9
Hong Kong 9
Houston 9
London 9
Pune 9
Boston 8
Helsinki 8
Nuremberg 8
Rio de Janeiro 8
The Dalles 8
Johannesburg 7
Norwalk 7
Seoul 7
Trieste 7
Atlanta 6
Brooklyn 6
Garden City 6
Moscow 6
Poplar 6
Tashkent 6
Amman 5
Chicago 5
Columbus 5
Fairfield 5
Lahore 5
Orem 5
Redwood City 5
Stockholm 5
Toronto 5
Ankara 4
Baghdad 4
Belo Horizonte 4
Benalla 4
Bologna 4
Cattolica 4
Chennai 4
Council Bluffs 4
Denver 4
Jacksonville 4
Manchester 4
Munich 4
Phoenix 4
Querétaro 4
Redmond 4
Seattle 4
Vicopisano 4
Washington 4
Bremen 3
Brussels 3
Campinas 3
City of London 3
Dhaka 3
Falls Church 3
Fremont 3
Genoa 3
Haiphong 3
Izmir 3
Montreal 3
Passo Fundo 3
Portsmouth 3
Riga 3
Salvador 3
San Francisco 3
Wroclaw 3
Addis Ababa 2
Andover 2
Bari 2
Brno 2
Buenos Aires 2
Buffalo 2
Caxias do Sul 2
Central 2
Chengdu 2
Cleveland 2
Totale 1.527
Salva come PNG Salva come JPEG
Nome #
Adult phenotype in Koolen-de Vries/KANSL1 haploinsufficiency syndrome 198
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 159
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 154
Clinical Features of Patients with Cervical Artery Dissection and Fibromuscular Dysplasia 136
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 128
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 125
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 122
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 117
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 113
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 113
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 111
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 110
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 106
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 106
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 104
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 103
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression 102
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 101
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 98
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 95
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 95
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 94
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 83
Totale 2.673
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.678
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.678
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/2022233 5 0 49 32 27 5 2 26 7 7 48 25
2022/2023422 58 67 30 64 18 66 15 25 55 3 12 9
2023/2024243 9 59 11 12 15 59 14 12 1 8 14 29
2024/2025472 9 13 31 19 43 20 19 15 57 96 89 61
2025/20261.242 200 37 69 162 245 69 197 55 81 61 59 7
Totale 2.673